Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants With Mutations Amenable to Exon 44 Skipping

NCT06244082 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.

NCT NCT06244082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06244082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants With Mutations Amenable to Exon 44 Skipping
Lead sponsor
Avidity Biosciences, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 22, 2024
Completion date
April 30, 2027
Enrollment
39 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dmd, duchenne, duchenne muscular dystrophy, exon 44